AChE: The Engine of Synaptic Precision

Acetylcholinesterase represents one of natureu2019s most catalytically efficient enzymes, operating at the physical limits of substrate diffusion to govern chemical neurotransmission. Without its instantaneous hydrolysis of acetylcholine, the human nervous system would collapse into persistent depolarizing paralysis, underscoring its pivotal role in neuromuscular coordination and cognitive function. Understanding its molecular architecture and catalytic kinetics is fundamental to neurobiology, pharmacology, and clinical therapeutics.

Acetylcholinesterase (AChE)

1. Concise Definition

Acetylcholinesterase (AChE) (EC 3.1.1.7) is a primary serine hydrolase enzyme localized predominantly within the central and peripheral nervous systems, the neuromuscular junction, and erythrocyte membranes. Its cardinal physiological role is the rapid hydrolytic cleavage of the neurotransmitter acetylcholine (ACh) into acetate and choline, thereby terminating synaptic transmission and preventing sustained, desensitizing muscle contraction or neuronal overexcitation.

Functioning with near-diffusion-limited catalytic proficiency, AChE hydrolyzes upward of 25,000 molecules of acetylcholine per second per active site. This extraordinary catalytic turnover ensures that after a vesicular burst of acetylcholine is released into the synaptic cleft, the signal remains sharp, discrete, and temporally bounded. The released choline is subsequently recaptured by high-affinity presynaptic choline transporters for de novo acetylcholine synthesis, rendering AChE an indispensable governor of cholinergic circuit homeostasis.

Beyond its classical catalytic mission, contemporary structural biology and molecular pharmacology recognize AChE as a multifunctional macromolecule. Alternative splicing generates structurally distinct variants that exhibit specialized tissue distributions and putative non-cholinergic functions, including cell adhesion, neurite outgrowth, neurogenesis, and modulation of programmed cell death across diverse physiological and pathological paradigms.

2. Etymology & Linguistic Origin

The term acetylcholinesterase is a systematic biochemical compound word derived from classical roots and modern chemical nomenclature. The prefix acetyl- originates from the Latin acetum, signifying u201cvinegaru201d or u201csour wine,u201d representing the two-carbon acyl radical ($CH_3CO-$). The root choline traces back to the Ancient Greek cholu0113 (u03c7u03bfu03bbu03ae), meaning u201cbile,u201d honoring its historical biochemical isolation from ox bile by Adolph Strecker in 1862.

The suffix ester was coined in the nineteenth century by German chemist Leopold Gmelin, derived as a portmanteau from Essigu00e4ther (literally u201cvinegar-etheru201d or ethyl acetate). The terminal biological suffix -ase, established to designate enzymes following the naming of diastase, stems from the Greek -asis, used in medical and biochemical terminology to signify a catalytic or transformative agent. Historically, the enzyme was distinguished from non-specific pseudocholinesterases by the designation u201ctrue cholinesteraseu201d or u201cspecific cholinesteraseu201d before the International Union of Biochemistry and Molecular Biology standardized its systematic name as acetylcholine acetylhydrolase.

3. Pronunciation & Grammatical Form

In standard academic and clinical English, the term is pronounced as follows:

• International Phonetic Alphabet (IPA): /u0259u02ccsiu02d0tau026alu02cckou028alu026anu02c8u025bstu0259u02ccreu026as/ or /u02ccu00e6su026atu026alu02cckou028alu026anu02c8u025bstu0259u02ccreu026az/
• Syllabification: au00b7ceu00b7tylu00b7chou00b7linu00b7esu00b7teru00b7ase
• Acronym: AChE (pronounced as individual letters u201cA-Ch-Eu201d or colloquially as an initialism)
• Part of Speech: Singular proper/mass biological noun; pluralized infrequently as acetylcholinesterases to refer to phylogenetic isoforms, molecular variants, or interspecies homologous enzymes.

4. Detailed Conceptual Explanation

To conceptualize acetylcholinesterase, one must examine its sophisticated three-dimensional structural architecture. The catalytic machinery resides within a remarkably deep and narrow hydrophobic gorge, approximately 20 u00c5ngstru00f6ms deep, penetrating into the core of the globular protein. This gorge is lined by 14 aromatic amino acid residues that guide the quaternary ammonium ion of acetylcholine through cation-pi interactions toward the active center situated near the base of the cleft.

The active center of AChE consists of two primary operational loci: the esteratic site and the anionic subsite. The esteratic site contains a classical catalytic triad composed of Serine-203, Histidine-440, and Glutamate-327 (numbering according to the canonical human enzyme). This triad mirrors the charge-relay network observed in other serine proteases and hydrolases, wherein the glutamate stabilizes the histidine ring, permitting histidine to act as a general base that deprotonates the serine hydroxyl group, generating a potent nucleophile that attacks the carbonyl carbon of acetylcholine.

The anionic subsite (specifically Trp-86 in human AChE) does not bind through simple electrostatic attraction, despite its historical moniker; rather, it coordinates the positively charged quaternary trimethylammonium group of acetylcholine via energetic cation-$\pi$ interactions between the positive charge and the electron-rich aromatic cloud of the tryptophan indole ring. Simultaneously, an adjacent acyl-binding pocket composed of Phe-295 and Phe-297 accommodates the methyl group of the acetyl moiety, providing spatial exclusion against bulkier substrates like butyrylcholine, thereby conferring strict substrate specificity.

At the rim of the active gorge sits an additional distinct functional domain: the peripheral anionic site (PAS), centered around Tyr-72, Asp-74, and Trp-286. The PAS functions as a dynamic electrostatic trap that catches acetylcholine molecules from the bulk solution and feeds them down the hydrophobic channel into the active center. Furthermore, the PAS acts as an allosteric regulator; binding of specific ligands, divalent cations, or excess substrate concentrations to the PAS can induce steric or conformational changes that modulate catalysis or mediate substrate inhibition at elevated concentrations.

The hydrolytic cycle progresses via a rapid two-step process: acylation followed by deacylation. First, the nucleophilic attack by Ser-203 yields a tetrahedral intermediate stabilized by an u201coxyanion holeu201d formed by the peptide backbone nitrogens of Gly-121, Gly-122, and Ala-204. The choline leaving group is expelled, yielding an acetylated enzyme intermediate. Second, a water molecule activated by His-440 attacks the acetylated serine, releasing acetic acid and regenerating the native, nucleophilic resting state of the catalytic triad within fractions of a microsecond.

5. Historical Development

The discovery and conceptual formulation of acetylcholinesterase mirror the broader trajectory of neurochemical transmission across the twentieth century. In 1914, Sir Henry Hallett Dale first identified the transient physiological actions of acetylcholine, presciently postulating that its ephemeral nature within tissue preparations was likely driven by an unusually active, specialized esterase present in the blood and peripheral tissues.

During the 1920s and 1930s, Austrian pharmacologist Otto Loewi unequivocally established chemical neurotransmission through his classic Vagusstoff experiments. Shortly thereafter, in 1926, Edgar Stedman and Ellen Stedman isolated and partially purified an ester-cleaving activity from blood serum that selectively hydrolyzed acetylcholine, officially introducing the term u201ccholine-esteraseu201d into biological nomenclature.

A critical conceptual breakthrough occurred in the 1940s when David Nachmansohn and his contemporaries demonstrated that the enzyme localized within the electric organ of the electric ray (Torpedo californica and Torpedo marmorata) exhibited an exceptionally high turnover velocity specifically tuned to acetylcholine, distinct from the non-specific esterases found in liver and serum. Nachmansohn crystallized the paradigm that this u201cspecificu201d cholinesterase was essential for biological conduction and neuromuscular bioelectricity.

The atomic-level understanding of AChE was revolutionized in 1991 when Joel Sussman, Israel Silman, and their colleagues solved the three-dimensional X-ray crystal structure of Torpedo californica AChE at 2.8 u00c5ngstru00f6m resolution. This structural landmark unveiled the deep hydrophobic gorge and disproved the long-standing belief that the anionic site relied on a negatively charged carboxylate residue, demonstrating instead the primacy of aromatic cation-$\pi$ interactions. Subsequent recombinant DNA cloning and crystallization of murine and human AChE during the late 1990s and early 2000s catalyzed rational structure-based drug design for neurodegenerative and toxicological interventions.

6. Theoretical Foundations

The kinetic behavior and biological operation of AChE are grounded in several overarching theoretical frameworks across physical chemistry, enzymology, and neurophysiology.

Foremost is the diffusion-limited enzyme theory, formalized by Smoluchowski and refined by Albery and Knowles. Under this framework, AChE is categorized as a u201ckinetically perfectu201d enzyme. Its catalytic rate constant ($k_{cat}/K_m pprox 1.6 imes 10^8 ext{ M}^{-1} ext{s}^{-1}$) is virtually identical to the frequency of physical molecular collisions between enzyme and substrate in aqueous solution. Evolution has refined the internal electric field and the electrostatic dipole moment of the AChE monomer, creating a funneling effect that drives the positively charged substrate toward the entrance of the gorge without requiring thermodynamic energy expenditure.

In neurophysiology, AChE is integral to the Quantal Hypothesis of Neurotransmission, pioneered by Bernard Katz and Paul Fatt. Following the exocytotic discharge of an acetylcholine quantum from synaptic vesicles at the motor endplate, the concentration of acetylcholine surges to approximately 1 millimolar across the synaptic gap. AChE ensures that this concentration drops to sub-micromolar levels within a millisecond. This prevents post-junctional nicotinic acetylcholine receptors from entering desensitized, closed states and enables muscle fibers to reliably follow high-frequency motor neuron discharge rates (up to 100 Hz) without failure.

Additionally, modern structural biochemistry applies the Conformational Plasticity and Induced-Fit Paradigm to AChE. Molecular dynamics simulations show that while the aromatic gorge is structurally rigid, it undergoes breathing motions and dynamic side-chain fluctuations (such as the aromatic u201cswinging gateu201d at Phe-338 and Trp-86). These subtle motions accommodate substrate entry, intermediate reorganization, and exit of the choline leaving group, reconciling the physical narrowness of the gorge with its near-instantaneous substrate throughput.

7. Key Components, Types & Dimensions

Acetylcholinesterase exhibits significant molecular diversity arising from a single structural gene through alternative mRNA splicing, distinct oligomerization states, and targeted post-translational modifications:

• Catalytic Domains: Every functional subunit comprises an $lpha/eta$-hydrolase fold, an aromatic gorge (~20 u00c5ngstru00f6ms deep), an active center triad (Ser-203, His-440, Glu-327), an anionic subsite (Trp-86), an acyl-binding pocket (Phe-295, Phe-297), an oxyanion hole, and a peripheral anionic site (PAS, centered at Trp-286).
• AChE-T (Tailed Variant): The primary transcript generated via alternative 3u2032 splicing that incorporates the u201cT-peptideu201d at the C-terminus. It represents the dominant functional isoform found within the brain, skeletal muscle, and peripheral nervous system. It can exist as monomers, dimers, or tetramers, and complexes with structural anchoring proteins.
• Asymmetric Collagen-Tailed Forms ($A_{12}, A_8, A_4$): Composed of one, two, or three AChE-T tetramers linked covalently via disulfide bridges to a triple-helical, collagenous tail structural subunit termed ColQ. This specialized quaternary complex anchors the enzyme to the synaptic basal lamina of vertebrate neuromuscular junctions.
• Hydrophobic-Tailed Forms ($G_4$ Membrane-Bound): Formed by AChE-T tetramers anchored to the external face of neuronal plasma membranes via a 20-kDa proline-rich membrane anchor protein termed PRiMA, constituting the primary functional form in the mammalian central nervous system.
• AChE-R (Readthrough Variant): A soluble, non-oligomerizing monomeric isoform produced when the alternative splicing machinery skips the regular downstream splice junctions during systemic stress or chemical exposure, leaving an extended C-terminal readthrough peptide that remains unanchored within the cytoplasm or extracellular fluid.
• AChE-H (Hydrophobic Variant): An isoform featuring a distinctive C-terminal cleavage and attachment of a glycosylphosphatidylinositol (GPI) anchor, directing the enzyme as a dimer to the outer leaflets of erythrocyte membranes and specific hematopoietic progenitor lines.

8. Examples & Illustrative Cases

The vital biological role of acetylcholinesterase is vividly illustrated in clinical pharmacology, medical toxicology, and clinical neurology:

• Myasthenia Gravis: An autoimmune disorder where autoantibodies target post-synaptic nicotinic receptors at the neuromuscular junction, leading to receptor internalization and severe skeletal muscle weakness. Pharmacological administration of reversible carbamate AChE inhibitors, such as pyridostigmine, slows acetylcholine hydrolysis. This extends the lifespan of acetylcholine within the synaptic cleft, elevating probability of remaining receptor activation and restoring motor endplate potential amplitude and muscle contractile force.
• Alzheimer’s Disease Therapeutics: Pathophysiological loss of basal forebrain cholinergic neurons (nucleus basalis of Meynert) leads to progressive deficits in memory and executive cognition. Centrally active reversible AChE inhibitorsu2014such as donepezil, rivastigmine, and galantamineu2014are prescribed to prolong endogenous cholinergic signaling across neocortical and hippocampal microcircuits, providing modest cognitive stabilization and symptomatic improvement.
• Organophosphate Intoxication: Exposure to synthetic organophosphorus compounds (e.g., nerve agents like sarin, soman, VX, or agricultural insecticides like chlorpyrifos) leads to irreversible phosphylation of Ser-203 within the esteratic active site. Inability to degrade acetylcholine precipitates a catastrophic cholinergic crisis characterized by excessive muscarinic stimulation (salivation, lacrimation, urination, defecation, bronchospasm, bradycardia) and nicotinic receptor depolarization block (muscle fasciculations followed by flaccid diaphragmatic paralysis and fatal respiratory arrest).
• Postoperative Reversal of Neuromuscular Blockade: Following surgical procedures utilizing non-depolarizing neuromuscular blocking drugs (e.g., rocuronium, vecuronium), anesthesiologists administer neostigmine in combination with an anticholinergic agent (such as glycopyrrolate) to rapidly displace the paralytic agent from motor endplate nicotinic receptors by transiently increasing endogenous acetylcholine levels while preventing excessive cardiac bradycardia.

9. Measurement & Assessment

Assessing AChE activity is vital for environmental toxicology, industrial occupational health, and neurobiological laboratory research. The historical and contemporary standard methodology is the Ellman Assay, developed by George L. Ellman and colleagues in 1961.

The Ellman method utilizes acetylthiocholine (ATC) as an artificial substrate analog. AChE hydrolyzes ATC into acetate and thiocholine. The liberated thiol group of thiocholine reacts stoichiometrically with the chromogenic reagent 5,5u2032-dithiobis-(2-nitrobenzoic acid) (DTNB, or Ellmanu2019s reagent), generating the yellow 5-thio-2-nitrobenzoate (TNB) dianion. The production rate of this chromophore is monitored spectrophotometrically at an absorbance wavelength of 412 nm, enabling high-precision kinetic quantification of enzymatic velocity ($V_{\max}$) and affinity ($K_m$).

To distinguish between genuine acetylcholinesterase and co-existing butyrylcholinesterase (BChE) within complex biological matrices (such as whole blood or tissue lysates), researchers employ selective pharmacological inhibitors. Compounds such as BW284c51 selectively inhibit AChE at nanomolar concentrations, whereas ethopropazine or iso-OMPA specifically inhibit BChE. Measuring enzymatic velocity with and without these selective blockers permits accurate resolution of both enzyme components.

In occupational monitoring, erythrocyte AChE activity is quantified to detect subclinical exposure to organophosphates or carbamates among agricultural workers. Because red blood cell AChE is biochemically identical to neuronal AChE, its suppression provides a direct, reliable surrogate marker of neurological vulnerability, superior to plasma cholinesterase (BChE) measurements that fluctuate substantially with liver function, pregnancy, and nutritional status.

10. Applications & Practical Significance

The applications of acetylcholinesterase science span an extensive array of medical, agricultural, and security sectors:

Within clinical medicine, AChE serves as both a therapeutic drug target and a diagnostic parameter. Beyond managing Alzheimeru2019s disease and myasthenia gravis, diagnosing Hirschsprungu2019s disease relies upon AChE histochemistry; suction rectal mucosal biopsies from neonates are stained for AChE to demonstrate hyperplastic, hypertrophic cholinergic nerve fibers in the aganglionic muscularis mucosae and submucosa, establishing a definitive histological confirmation.

In toxicology and chemical defense, understanding the molecular mechanisms of AChE phosphylation has led to the design of medical countermeasures against chemical weapons. Nucleophilic oximes, such as pralidoxime (2-PAM) and obidoxime, were engineered to dock within the active gorge, position an oxime oxygen atom adjacent to the adduct-bound phosphorus atom, and displace the organophosphoryl moiety via an $S_N2$ nucleophilic attack, thereby dephosphylating and reactivating the functional serine residue before the irreversible molecular phenomenon of u201cagingu201d (dealkylation of the phosphyl group) locks the enzyme into permanent inactivation.

In agricultural pest management, synthetic AChE inhibitors (carbamates and organophosphates) were historically developed as broad-spectrum insecticides. While contemporary agricultural frameworks increasingly transition toward neonicotinoids and diamides to minimize off-target mammalian toxicity, AChE remains a focal subject of resistance monitoring, as pest populations frequently evolve single-point mutations within the AChE catalytic gorge (e.g., G119S and F331W) that reduce insecticide sensitivity.

11. Research & Empirical Evidence

Seminal investigations across structural biology, molecular genetics, and neuropharmacology continue to expand our understanding of AChE function and structural biology:

Foundational structural work led by Sussman et al. (1991) and subsequent high-resolution crystallographic studies by Bourne, Marchot, and Taylor uncovered the conformational architecture of murine and human AChE complexes with classic inhibitors. Structural analyses of donepezil bound to AChE showed that this drug spans the entire depth of the aromatic gorge, simultaneously interacting with the catalytic active site via its piperidine ring and the peripheral anionic site via its indanone moiety, without chemically reacting with the Ser-203 hydroxyl. This elucidated the molecular structural basis for its reversible, non-competitive inhibition kinetics.

Genetic knock-out studies in rodents conducted by researchers like Jeru00f4me Duclert and colleagues challenged historic assumptions regarding absolute embryonic lethality. Remarkably, mice engineered with homozygous targeted disruption of the AChE gene ($AChE^{-/-}$), as documented by Xie et al. (2000), survive through birth and can live into early adulthood, despite severe autonomic, cognitive, and physical deficits. This revealed unexpected neurodevelopmental compensation, wherein high concentrations of butyrylcholine and butyrylcholinesterase partially assume the role of terminating cholinergic transmission in synaptic loci when AChE is entirely absent.

Contemporary neuroepigenetics and RNA biology research, notably led by Hermona Soreq and collaborators, has dissected the non-canonical roles of the AChE-R splice variant during environmental and psychological stress. Under acute systemic or emotional stressors, a transient shift from AChE-T to alternative AChE-R transcription occurs in both central neurons and circulating leukocytes, yielding structural elevation of free monomeric AChE that influences microglial activation, cytokine profiles, and neuroinflammatory signaling cascades independent of traditional synaptic transmission.

12. Cultural & Cross-Cultural Considerations

Cultural and geopolitical perspectives on acetylcholinesterase revolve around environmental justice, industrial occupational regulation, and international chemical weapon treaties.

In low- and middle-income agricultural economies across South Asia, Latin America, and Sub-Saharan Africa, widespread application of organophosphorus pesticides presents severe public health and environmental challenges. Occupational access and variable availability of personal protective equipment make pesticide-mediated AChE inhibition a primary cause of accidental toxicity and self-poisoning. The World Health Organization (WHO) has actively supported educational initiatives and point-of-care erythrocyte AChE test biosensors to improve safety compliance and surveillance in farming communities worldwide.

From an international security standpoint, the Weaponization of AChE inhibitors has influenced global arms treaties. The 1993 Chemical Weapons Convention (CWC), administered by the Organisation for the Prohibition of Chemical Weapons (OPCW), emerged largely in response to the proliferation of lethal AChE-inactivating nerve agents such as tabun, sarin, soman, and the modern Novichok family of organophosphorus compounds. The biological potency of irreversible AChE arrest has solidified its place in humanitarian international law, leading to strict, legally binding prohibitions on the synthesis and stockpiling of organophosphorus nerve toxins.

13. Criticisms, Debates & Limitations

Despite more than a century of investigation, controversies and clinical debates regarding AChE and its pharmacological manipulation remain active:

• The Cholinergic Hypothesis of Alzheimer’s Disease: Although acetylcholinesterase inhibitors represent standard symptomatic therapeutics for mild-to-moderate Alzheimer’s dementia, critics point out their minimal impact on underlying neurodegenerative pathology. Enhancing acetylcholine levels fails to prevent neurofibrillary tau aggregation, amyloid-$eta$ deposition, or progressive loss of cortical synapses. The clinical debate persists regarding whether the modest symptomatic efficacy justifies the frequent gastrointestinal, cardiovascular (bradycardia, syncope), and sleep-disturbing adverse events associated with sustained AChE suppression.
• Non-Catalytic / Non-Cholinergic Pathogenic Roles: Structural researchers have discovered that the peripheral anionic site (PAS) of AChE interacts directly with monomeric and oligomeric amyloid-$eta$ peptides, accelerating their aggregation into neurotoxic fibrillar plaques. This observation ignited debate over whether AChE acts as an active pathogenic driver in Alzheimer’s disease progression, leading to experimental developments of u201cdual-siteu201d or multi-target-directed inhibitors designed to suppress catalytic esterase activity while sterically shielding the PAS from amyloid interactions.
• The Gulf War Illness Controversy: Following the 1991 Gulf War, debates emerged regarding the chronic multisymptom illness reported by veterans. Hypotheses centered around neurotoxic synergism between prophylactic pyridostigmine bromide (a reversible AChE inhibitor administered as protection against chemical attack), transdermal DEET insect repellents, and low-level organophosphate exposures, with ongoing discussions about whether chronic non-catalytic AChE alterations contribute to persistent neuroimmune dysregulation.
• Oxime Efficacy in Organophosphate Poisoning: Real-world clinical trials evaluating the therapeutic utility of pralidoxime in agricultural organophosphate poisonings have yielded conflicting results. Skeptics note that in cases involving rapidly u201cagingu201d organophosphates (such as dimethyl pesticides), oximes often fail to confer clear clinical survival benefits over standard supportive care and aggressive atropine monotherapy, underscoring the urgent need for next-generation catalytic bioscavengers.

14. Related Terms & Distinctions

Acetylcholinesterase must be rigorously demarcated from related proteins, receptors, and functional substrates across pharmacology:

• Butyrylcholinesterase (BChE): Historically termed u201cpseudocholinesteraseu201d or u201cserum cholinesterase,u201d BChE is synthesized primarily by the liver and circulates freely in plasma. While both enzymes hydrolyze choline esters, BChE preferentially hydrolyzes larger esters like butyrylcholine and lacks the steric aromatic gate (Phe-295 and Phe-297) found in AChE, rendering its active gorge broader and more permissive to bulky synthetic molecules, local anesthetics (e.g., procaine), and succinylcholine.
• Choline Acetyltransferase (ChAT): The complementary biosynthetic enzyme responsible for assembling acetylcholine from acetyl-CoA and choline within the presynaptic terminal cytoplasm. Whereas AChE mediates catabolism and signal termination, ChAT mediates biosynthesis and signal creation.
• Nicotinic Acetylcholine Receptors (nAChR): Ligand-gated ion channel complexes situated on the postsynaptic membrane that undergo conformational opening to allow $Na^+$ influx upon binding acetylcholine. AChE is the hydrolytic regulator that limits the duration of nAChR channel openings.
• Muscarinic Acetylcholine Receptors (mAChR): Seven-transmembrane G-protein coupled receptors ($M_1$ through $M_5$) that mediate slower metabotropic cholinergic signaling throughout the central and autonomic nervous systems, dynamically protected by AChE against chronic agonist-induced receptor internalization.
• Carboxylesterases: A broader superfamily of mammalian $lpha/eta$-hydrolase enzymes that hydrolyze xenobiotic esters and amides, possessing broader substrate promiscuity and lacking the high-affinity cation-$\pi$ aromatic architecture characteristic of AChE.

15. Summary / Key Takeaways

Acetylcholinesterase remains one of the foundational paradigms of modern molecular neuroscience, kinetic enzymology, and structural pharmacology. Operating as an exceptionally rapid hydrolase, AChE regulates cholinergic transmission across autonomic ganglia, central neural networks, and neuromuscular junctions. Its deep, aromatic gorge houses an elegant Ser-His-Glu catalytic triad supported by specialized sub-domains that coordinate, acylate, and hydrolyze acetylcholine within sub-millisecond timeframes.

Pharmacologically, AChE serves as an indispensable target across multiple sectors: its selective, reversible inhibition elevates endogenous acetylcholine to treat Alzheimer’s disease and myasthenia gravis, while its irreversible inhibition by organophosphates and chemical nerve agents causes severe cholinergic poisoning that requires rapid intervention with muscarinic antagonists and oxime reactivators. Ongoing research continues to reveal its alternative splice variants, its contributions to neuroinflammation, and its potential non-catalytic roles in neurodegenerative proteinopathies, reaffirming this enzyme’s enduring relevance to contemporary biomedical science.

References

• Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013). Acetylcholinesterase inhibitors: Pharmacology and toxicology. Current Neuropharmacology, 11(3), 315u2013335. https://doi.org/10.2174/1570159X11311030006
• Dale, H. H. (1914). The action of certain esters and ethers of choline, and their relation to muscarine. Journal of Pharmacology and Experimental Therapeutics, 6(2), 147u2013190.
• Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology, 7(2), 88u201395. https://doi.org/10.1016/0006-2952(61)90145-9
• Massouliu00e9, J., Pezzementi, L., Bon, S., Krejci, E., & Vallette, F. M. (1993). Molecular and cellular biology of cholinesterases. Progress in Neurobiology, 41(1), 31u201391. https://doi.org/10.1016/0301-0082(93)90040-Y
• Quinn, D. M. (1987). Acetylcholinesterase: Enzyme structure, reaction dynamics, and virtual transition states. Chemical Reviews, 87(5), 955u2013979. https://doi.org/10.1021/cr00081a005
• Silman, I., & Sussman, J. L. (2005). Acetylcholinesterase: u2018Classicalu2019 and u2018non-classicalu2019 functions and pharmacology. Current Opinion in Pharmacology, 5(3), 293u2013302. https://doi.org/10.1016/j.coph.2005.01.014
• Soreq, H., & Seidman, S. (2001). Acetylcholinesteraseu2014new roles for an old enzyme. Nature Reviews Neuroscience, 2(4), 294u2013302. https://doi.org/10.1038/35067589
• Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., & Silman, I. (1991). Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein. Science, 253(5022), 872u2013879. https://doi.org/10.1126/science.1678899
• Taylor, P., & Radic, Z. (1994). The biology of acetylcholinesterase. Annual Review of Pharmacology and Toxicology, 34(1), 281u2013320. https://doi.org/10.1146/annurev.pa.34.040194.001433
• Xie, W., Stribley, J. A., Chatonnet, A., Wilder, P. J., Rizzino, A., McComb, R. D., Taylor, P., Hinrichs, S. H., & Lockridge, O. (2000). Postnatal development of acetylcholinesterase-deficient mice: Compensation by butyrylcholinesterase in peripheral tissues. The Journal of Pharmacology and Experimental Therapeutics, 293(3), 896u2013902.